The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 Infectivity and Env-Dependent...

Area of Science:

• Virology
• Drug Discovery
• Immunology

Background:

• Current antiretroviral therapies do not target the incorporation of envelope glycoproteins into new virus particles.
• Oleandrin, a botanical glycoside from Nerium oleander, previously demonstrated inhibition of human immunodeficiency virus type-1 (HIV-1) infectivity and gp120 envelope glycoprotein levels.
• Human T-cell leukemia virus type-1 (HTLV-1) is a related enveloped retrovirus and an emerging tropical infectious agent.

Purpose of the Study:

• To investigate the potential of oleandrin and N. oleander extracts in inhibiting HTLV-1 infectivity and transmission.
• To explore oleandrin's mechanism of action against HTLV-1, particularly its effect on viral synapse formation.

Main Methods:

• Treatment of HTLV-1+ lymphoma T-cells with oleandrin or N. oleander extract.
• Analysis of viral replication and release of p19Gag-containing particles.
• Assessing the infectivity of collected virus particles on primary human peripheral blood mononuclear cells (huPBMCs).
• Co-culture assays to evaluate inhibition of virus transmission and virological synapse formation.

Main Results:

• Oleandrin and N. oleander extract did not significantly inhibit HTLV-1 replication or particle release.
• Virus particles from treated cells showed reduced infectivity on huPBMCs.
• Both oleandrin and the crude phytoextract effectively inhibited virological synapse formation and HTLV-1 transmission in co-culture assays.

Conclusions:

• Oleandrin and N. oleander extracts inhibit HTLV-1 transmission by disrupting virological synapse formation.
• These findings suggest oleandrin possesses broad-spectrum antiviral activity against enveloped viruses.
• Oleandrin targets a crucial stage in the viral lifecycle—envelope glycoprotein incorporation—not currently addressed by modern HAART.